• Alumis Inc. recently reported its first-quarter 2026 results, with revenue of US$1.74 million compared with US$17.39 million a year earlier and a net loss of US$93.05 million versus US$98.96 million.
• Despite the sharp revenue drop, the company narrowed its basic loss per share from continuing operations to US$0.74, down from US$1.82, highlighting shifting cost and earnings dynamics.
• Next, we’ll examine how Alumis’s sharply lower revenue but reduced loss per share shapes the company’s broader investment narrative and outlook.

Find 49 companies with promising cash flow potential yet trading below their fair value.

What Is Alumis' Investment Narrative?

To own Alumis today, you have to believe the TYK2 pipeline, especially envudeucitinib in psoriasis and ESK-001 in SLE, can eventually justify heavy ongoing investment and recent dilution. The latest quarter’s US$1.74 million revenue and US$93.05 million net loss reinforce that this is still a clinical-stage, cash-consuming story, even though the loss per share improved. Near term, the key catalysts remain regulatory and clinical: the planned NDA filing for envudeucitinib in the second half of 2026 and LUMUS Phase 2b data in the third quarter of 2026. The new results do little to change those timelines, but the sharp revenue step-down keeps funding and balance sheet risk firmly in focus, especially after two recent equity offerings and a past going concern flag from auditors.

However, the combination of ongoing losses and prior going concern commentary is something investors should not ignore. Our comprehensive valuation report raises the possibility that Alumis is priced higher than what may be justified by its financials.

Exploring Other Perspectives

The Simply Wall St Community’s three fair value estimates span from just US$2.11 to US$40.10 per share, showing how far apart individual views can be. Set that against Alumis’s shrinking revenue base and continued sizeable quarterly losses, and it becomes clear why many market participants are focusing on funding risk and execution around the key TYK2 milestones.

Explore 3 other fair value estimates on Alumis - why the stock might be worth as much as 82% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alumis research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Alumis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alumis' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.